View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
February 18, 2020updated 12 Jul 2022 11:57am

Recardio to continue Phase II trial of dutogliptin

Life science company Recardio is set to continue the Phase II clinical trial of its dutogliptin drug in combination with filgrastim in severe heart attack patients.

Life science company Recardio is set to continue the Phase II clinical trial of its dutogliptin drug in combination with filgrastim in severe heart attack patients.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The drug combination is being evaluated for the ability to restore lost myocardial function in patients who had stent placement via percutaneous coronary intervention.

Following an interim analysis of the trial, a Data Safety Monitoring Board recommended that the randomised, double-blind, placebo-controlled study can continue without any changes. This will enable participating trial sites to continue patient enrolment.

Recardio executive chairman Roman Schenk said: “The interim analysis was a critical milestone to completion of the study. We are encouraged by the efforts of the clinical investigators and look forward to the conclusion of the trial by this year.”

Dutogliptin is designed as a regenerative medicine to reduce and repair heart muscle injury. It acts as an inhibitor of dipeptidylpeptidase-IV (DPP4) enzyme, which is involved in the degradation of stromal-derived factor-1α (SDF-1α).

The Phase II trial is assessing a 60mg, twice-a-day, subcutaneous injection of dutogliptin for 14 days combined with 10µg/kg, daily, subcutaneous dose of filgrastim for five days. It is set to enrol a total of 120 patients.

The primary endpoint of the study is safety and tolerability of the combination when compared to placebo in adults with ST-elevation myocardial infarction (STEMI).

Meanwhile, the trial’s secondary objectives include preliminary efficacy of dutogliptin plus filgrastim, along with pharmacokinetics and pharmacodynamics of dutogliptin in a study subset.

The study will also assess exploratory endpoints of the combination’s effects on plasma stromal cell-derived factor (SDF)-1a levels and plasma biomarkers.

Initiated in 2018, the Phase II trial is expected to be completed in October this year.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena